<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04683666</url>
  </required_header>
  <id_info>
    <org_study_id>CEIC13-2</org_study_id>
    <nct_id>NCT04683666</nct_id>
  </id_info>
  <brief_title>Cardiovascular Risk Factors of Medical and Septic Complications After Laparoscopic Bariatric Surgery</brief_title>
  <official_title>Cardiovascular Risk Factors of Medical and Septic Complications After Laparoscopic Bariatric Surgery. A Prospective Cohort Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital General Universitario Elche</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dr. Negrin University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital General Universitario Elche</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective, observational study of all morbidly obese patients undergoing laparoscopic&#xD;
      Roux-en-Y gastric bypass (LRYGB) or laparoscopic sleeve gastrectomy (LSG) was performed. We&#xD;
      evaluated preoperative comorbidities and cardiovascular risk factors, and the appearance of&#xD;
      postoperative complications up to 90 days after surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study aimed to identify potential cardiovascular risk factors for postoperative medical&#xD;
      and septic complications after bariatric surgery.&#xD;
&#xD;
      A prospective, observational study of all morbidly obese patients undergoing laparoscopic&#xD;
      Roux-en-Y gastric bypass (LRYGB) or laparoscopic sleeve gastrectomy (LSG) was performed. We&#xD;
      evaluated preoperative comorbidities and cardiovascular risk factors, and the appearance of&#xD;
      postoperative complications up to 90 days after surgery.&#xD;
&#xD;
      Evaluated cardiovascular risk factors include age, the presence of tobacco habit,&#xD;
      preoperative diagnosis of T2D, hypertension, dyslipidemia, cardiopathies (including&#xD;
      arrhythmias, ischemic cardiopathy or congestive cardiac failure), strokes, Charlson index and&#xD;
      analytical parameters of the lipid (triglycerids, total cholesterol and the subfractions High&#xD;
      Density Lipoproteins (HDL-cholesterol) and Low Density Lipoproteins (LDL-cholesterol) and&#xD;
      glycemic profile (fasting glucose and glycated hemoglobin). Cardiovascular risk factors, such&#xD;
      as the Framingham risk score, were analyzed.&#xD;
&#xD;
      Primary outcomes were the appearance of medical and septic postoperative complications.&#xD;
      Medical complications include cardiovascular complications (new onset or impairment of acute&#xD;
      heart infarction, arrhythmias, cardiac failure or stroke), respiratory complications&#xD;
      (pneumonia or respiratory failure) and acute renal failure. Septic complications include,&#xD;
      urinary tract infections, incisional or organ/space surgical site infection (SSI), pneumonia&#xD;
      or bacteriemia of other origin.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 15, 2013</start_date>
  <completion_date type="Actual">June 15, 2020</completion_date>
  <primary_completion_date type="Actual">September 1, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Medical complications</measure>
    <time_frame>90 days after surgery</time_frame>
    <description>Medical complications include cardiovascular complications (new onset or impairment of acute heart infarction, arrhythmias, cardiac failure or stroke), respiratory complications (pneumonia or respiratory failure) and acute renal failure.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Septic complications</measure>
    <time_frame>90 days after surgery</time_frame>
    <description>Septic complications include, urinary tract infections, incisional or organ/space surgical site infection (SSI), pneumonia or bacteriemia of other origin.</description>
  </primary_outcome>
  <enrollment type="Actual">177</enrollment>
  <condition>Complication of Surgical Procedure</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Bariatric surgery</intervention_name>
    <description>Laparoscopic Roux-en-Y gastric bypass (LRYGB) or laparoscopic sleeve gastrectomy (LSG), as primary bariatric procedures, were performed. ^Postoperative complications were assessed.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The patients included were morbidly obese patients or patients with severe obesity&#xD;
        associated with obesity-related comorbidities&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  BMI &gt;40 Kg/m2&#xD;
&#xD;
          -  BMI &gt;35 Kg/m2 associated with obesity-related comorbidities&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  ASA IV&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Asuncion Acosta</last_name>
    <role>Study Director</role>
    <affiliation>Hospital Universitario Dr Negrin</affiliation>
  </overall_official>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 21, 2020</study_first_submitted>
  <study_first_submitted_qc>December 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 24, 2020</study_first_posted>
  <last_update_submitted>December 21, 2020</last_update_submitted>
  <last_update_submitted_qc>December 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital General Universitario Elche</investigator_affiliation>
    <investigator_full_name>Jaime Ruiz-Tovar, MD, PhD</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

